Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Raised to $25.00

Phathom Pharmaceuticals (NASDAQ:PHAT) had its target price raised by Guggenheim from $20.00 to $25.00 in a research report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. Barclays initiated coverage on Phathom Pharmaceuticals in a research note on Monday, December 8th. They set an “equal weight” rating and a $16.00 price objective for the company. Raymond James Financial began coverage on Phathom Pharmaceuticals in a report on Thursday, December 11th. They set a “strong-buy” rating and a $28.00 target price on the stock. Stifel Nicolaus set a $28.00 target price on Phathom Pharmaceuticals in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Craig Hallum reissued a “buy” rating and set a $22.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Phathom Pharmaceuticals Trading Down 7.4%

Shares of NASDAQ PHAT opened at $12.56 on Friday. Phathom Pharmaceuticals has a 1 year low of $2.21 and a 1 year high of $18.31. The firm’s 50-day moving average is $14.30 and its 200-day moving average is $13.52. The firm has a market capitalization of $989.73 million, a PE ratio of -4.10 and a beta of 0.51.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $57.58 million during the quarter, compared to analyst estimates of $57.44 million. As a group, equities research analysts anticipate that Phathom Pharmaceuticals will post -4.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its stake in Phathom Pharmaceuticals by 508.2% in the 1st quarter. AQR Capital Management LLC now owns 107,399 shares of the company’s stock worth $673,000 after purchasing an additional 89,741 shares during the period. AlphaQuest LLC lifted its holdings in shares of Phathom Pharmaceuticals by 2,127.2% in the second quarter. AlphaQuest LLC now owns 32,206 shares of the company’s stock valued at $309,000 after purchasing an additional 30,760 shares in the last quarter. Savant Capital LLC bought a new stake in shares of Phathom Pharmaceuticals in the second quarter valued at about $113,000. Geode Capital Management LLC boosted its position in shares of Phathom Pharmaceuticals by 5.3% during the second quarter. Geode Capital Management LLC now owns 1,069,927 shares of the company’s stock worth $10,263,000 after buying an additional 53,504 shares during the period. Finally, Intech Investment Management LLC grew its holdings in shares of Phathom Pharmaceuticals by 31.2% during the second quarter. Intech Investment Management LLC now owns 28,192 shares of the company’s stock worth $270,000 after buying an additional 6,708 shares in the last quarter. 99.01% of the stock is currently owned by institutional investors and hedge funds.

Key Phathom Pharmaceuticals News

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target to $25 and upgraded PHAT to a “buy”, implying large upside from current levels — a clear analyst endorsement that can support the stock over the medium term. Guggenheim PT Raise (Benzinga)
• Positive Sentiment: Management issued FY‑2026 revenue guidance of $320M–$345M and reiterated a target of operating profitability beginning in Q3 2026 and for the full year — guidance above street revenue consensus and a near‑term path to profitability are constructive for valuation. 2026 Guidance (Seeking Alpha)
• Positive Sentiment: Q4 results beat: EPS of ($0.08) vs. consensus ($0.09) and revenue $57.6M vs. $57.4M; FY2025 revenue jumped to $175.1M (≈217% YoY) and VOQUEZNA® prescriptions topped 1.1M — evidence of strong commercial traction. Q4 Results & Press Release (GlobeNewswire)
• Neutral Sentiment: Company says it strengthened its balance sheet via a $130M equity offering and a term‑debt modification; management reported modest net cash usage — this improves runway but the equity raise can be dilutive, which may temper upside. Balance Sheet Update (GlobeNewswire)
• Neutral Sentiment: Earnings materials (presentation and call transcript) are available for review — useful for details on sales cadence, launch math and timing to profitability but not new headlines by themselves. Earnings Presentation (Seeking Alpha) Earnings Transcript (Seeking Alpha)
• Neutral Sentiment: Preview and analyst commentary published around the Q4 print are available for reading; they summarize expectations and may influence near‑term sentiment but contain no fresh operational surprises. Q4 Preview (Yahoo Finance)

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.